72 reports of this reaction
3.6% of all ACETAMINOPHEN, DEXTROMETHORPHAN HBR, PHENYLEPHRINE HCL reports
#3 most reported adverse reaction
NASOPHARYNGITIS is the #3 most commonly reported adverse reaction for ACETAMINOPHEN, DEXTROMETHORPHAN HBR, PHENYLEPHRINE HCL, manufactured by The Procter & Gamble Manufacturing Company. There are 72 FDA adverse event reports linking ACETAMINOPHEN, DEXTROMETHORPHAN HBR, PHENYLEPHRINE HCL to NASOPHARYNGITIS. This represents approximately 3.6% of all 1,997 adverse event reports for this drug.
Patients taking ACETAMINOPHEN, DEXTROMETHORPHAN HBR, PHENYLEPHRINE HCL who experience nasopharyngitis should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
NASOPHARYNGITIS is moderately reported among ACETAMINOPHEN, DEXTROMETHORPHAN HBR, PHENYLEPHRINE HCL users, representing a notable but not dominant share of adverse events.
In addition to nasopharyngitis, the following adverse reactions have been reported for ACETAMINOPHEN, DEXTROMETHORPHAN HBR, PHENYLEPHRINE HCL:
The following drugs have also been linked to nasopharyngitis in FDA adverse event reports:
NASOPHARYNGITIS has been reported as an adverse event in 72 FDA reports for ACETAMINOPHEN, DEXTROMETHORPHAN HBR, PHENYLEPHRINE HCL. This does not prove causation, but indicates an association observed in post-market surveillance data.
NASOPHARYNGITIS accounts for approximately 3.6% of all adverse event reports for ACETAMINOPHEN, DEXTROMETHORPHAN HBR, PHENYLEPHRINE HCL, making it one of the most commonly reported side effect.
If you experience nasopharyngitis while taking ACETAMINOPHEN, DEXTROMETHORPHAN HBR, PHENYLEPHRINE HCL, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.